AR018609A1 - Composicion farmaceutica solida estabilizada que contiene un derivado de acido 4-amino-3-sustituido-butanoico y proceso para su preparacion. - Google Patents

Composicion farmaceutica solida estabilizada que contiene un derivado de acido 4-amino-3-sustituido-butanoico y proceso para su preparacion.

Info

Publication number
AR018609A1
AR018609A1 ARP990102312A ARP990102312A AR018609A1 AR 018609 A1 AR018609 A1 AR 018609A1 AR P990102312 A ARP990102312 A AR P990102312A AR P990102312 A ARP990102312 A AR P990102312A AR 018609 A1 AR018609 A1 AR 018609A1
Authority
AR
Argentina
Prior art keywords
amino
substituted
preparation
pharmaceutical composition
composition containing
Prior art date
Application number
ARP990102312A
Other languages
English (en)
Inventor
Akira Aomatsu
Hachioji-Shi Matsuka
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR018609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR018609A1 publication Critical patent/AR018609A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP990102312A 1998-05-15 1999-05-14 Composicion farmaceutica solida estabilizada que contiene un derivado de acido 4-amino-3-sustituido-butanoico y proceso para su preparacion. AR018609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13311298 1998-05-15

Publications (1)

Publication Number Publication Date
AR018609A1 true AR018609A1 (es) 2001-11-28

Family

ID=15097099

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102312A AR018609A1 (es) 1998-05-15 1999-05-14 Composicion farmaceutica solida estabilizada que contiene un derivado de acido 4-amino-3-sustituido-butanoico y proceso para su preparacion.

Country Status (25)

Country Link
US (1) US8623407B2 (es)
EP (1) EP1077691B1 (es)
JP (3) JP4564607B2 (es)
KR (1) KR100669280B1 (es)
CN (1) CN100337687C (es)
AR (1) AR018609A1 (es)
AU (1) AU769038B2 (es)
BR (1) BR9910494B1 (es)
CO (1) CO5060516A1 (es)
CU (1) CU23051A3 (es)
GT (1) GT199900068A (es)
HK (2) HK1036407A1 (es)
HU (1) HU228772B1 (es)
ID (1) ID26395A (es)
IS (1) IS2983B (es)
MY (1) MY127953A (es)
NO (1) NO329116B1 (es)
PA (1) PA8472701A1 (es)
PE (1) PE20000542A1 (es)
PL (1) PL205145B1 (es)
SV (1) SV1999000063A (es)
TW (1) TW592691B (es)
UY (1) UY25513A1 (es)
WO (1) WO1999059572A1 (es)
ZA (1) ZA200006483B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
HUP0301919A3 (en) * 2000-06-16 2006-01-30 Teva Pharma Stable gabapentin having ph within a controlled range
EP1289364B1 (en) * 2000-06-16 2003-12-10 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
EP1334732B1 (en) * 2000-11-17 2010-06-02 Takeda Pharmaceutical Company Limited Pharmaceutical preparation of n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4 b]furan-8-yl)ethyl]propionamide coated with a copolyvidone-containing coating free of polyethylene glycol
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
CN1921839A (zh) * 2004-01-19 2007-02-28 兰贝克赛实验室有限公司 加巴喷丁的稳定缓释口服剂型及其制备方法
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
KR20080096779A (ko) * 2006-01-20 2008-11-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 필름 코팅정
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2298286B8 (en) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Process for dewatering of product powders
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2680823B1 (en) * 2011-02-28 2024-05-15 Nano4M Ltd Binder powders
WO2015114509A1 (en) 2014-01-28 2015-08-06 Ranbaxy Laboratories Limited Stabilized gastroretentive tablets of pregabalin
CA2953225A1 (en) 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
JP7276760B2 (ja) * 2016-12-08 2023-05-18 日本ケミファ株式会社 4-アミノ-3-ブタン酸類縁体含有固形製剤
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019052147A (ja) * 2017-09-13 2019-04-04 大原薬品工業株式会社 化学的な安定性が改善された、プレガバリン含有口腔内崩壊錠
JP7138666B2 (ja) * 2018-01-24 2022-09-16 大原薬品工業株式会社 γ-アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
MX2020011130A (es) * 2018-04-24 2022-09-09 Shionogi & Co Forma de dosificacion solida que tiene excelente estabilidad.
BR112020021059B1 (pt) 2018-04-24 2022-08-30 Shionogi & Co., Ltd Forma de dosagem sólida

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115553A (en) * 1973-12-10 1978-09-19 Armour Pharmaceutical Company Antacid tablets
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
GB8504093D0 (en) * 1985-02-18 1985-03-20 Ici Plc Alkene alkyne/cycloalkylene derivatives
US4486412A (en) * 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) * 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder

Also Published As

Publication number Publication date
US8623407B2 (en) 2014-01-07
BR9910494B1 (pt) 2011-11-01
UY25513A1 (es) 1999-07-19
HUP0101791A3 (en) 2003-03-28
CO5060516A1 (es) 2001-07-30
NO20005765D0 (no) 2000-11-14
HK1036407A1 (en) 2002-01-04
NO329116B1 (no) 2010-08-30
HUP0101791A2 (hu) 2001-10-28
BR9910494A (pt) 2001-01-09
CN1575817A (zh) 2005-02-09
SV1999000063A (es) 2000-07-31
NO20005765L (no) 2000-11-14
GT199900068A (es) 2002-01-18
JP3527729B2 (ja) 2004-05-17
IS5647A (is) 2000-09-29
AU4073399A (en) 1999-12-06
ZA200006483B (en) 2002-04-09
JP3944150B2 (ja) 2007-07-11
JP4564607B2 (ja) 2010-10-20
WO1999059572A1 (en) 1999-11-25
JP2003055211A (ja) 2003-02-26
CN100337687C (zh) 2007-09-19
CU23051A3 (es) 2005-06-24
PL344219A1 (en) 2001-10-08
HU228772B1 (en) 2013-05-28
WO1999059572A8 (en) 2000-12-21
KR20010043610A (ko) 2001-05-25
PL205145B1 (pl) 2010-03-31
EP1077691B1 (en) 2008-09-10
KR100669280B1 (ko) 2007-01-17
JP2004043506A (ja) 2004-02-12
ID26395A (id) 2000-12-21
MY127953A (en) 2007-01-31
JP2000034227A (ja) 2000-02-02
PE20000542A1 (es) 2000-08-10
EP1077691A1 (en) 2001-02-28
AU769038B2 (en) 2004-01-15
HK1072729A1 (en) 2005-09-09
IS2983B (is) 2017-09-15
TW592691B (en) 2004-06-21
US20090156677A1 (en) 2009-06-18
PA8472701A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
AR018609A1 (es) Composicion farmaceutica solida estabilizada que contiene un derivado de acido 4-amino-3-sustituido-butanoico y proceso para su preparacion.
BR9810802B1 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto.
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
PT1150961E (pt) Derivados do acido pirazolecarboxilico processo para a sua preparacao e as composicoes farmaceuticas que os contem
DE69811735D1 (de) Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
PT812195E (pt) Composicao farmaceutica para compostos de piperidinoalcanol
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
HUP0103376A3 (en) New 3-aryl-2-hydroxypropionic acid derivative, pharmaceutical compositions containing it, process for their preparation and their use
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
BR9801606B1 (pt) composto, processo para sua preparação, substáncia farmacêutica, uso do composto e processo para a produção de uma substáncia farmacêutica.
BR9602933A (pt) Compostos processos para preparação de composto e de composição farmacêutica e composto
PT95991A (pt) Processo para a preparacao de composicoes farmaceuticas contendo benzodiazepina
PT885204E (pt) Novos derivados de arilglicinamida, processo para a sua preparacao e composicoes farmaceuticas que contem estes compostos
IL131751A0 (en) Aryl-or heteroarylsulfonamide substituted hydroxamic acid derivatives process for their preparation and their use as pharmaceuticals
BR9808422B1 (pt) composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
BR9711340A (pt) Composto composi-Æo farmac-utica e processo para preparar um composto
BR9607095A (pt) Composto composição farmacêutica e processos para fabricar e para administrar um composto
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
IL129420A (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives having matrix metalloprotease inhibiting properties, pharmaceutical compositions containing them and a method for their preparation
PT801561E (pt) Composicao e metodos para a entrega transdermica de drogas labeis a acido
BR9602025A (pt) Composto composição farmacêutica uso e processo para a preparação de um composto
PT1118610E (pt) Novos derivados de benzeno-sulfonamida processo para a sua preparacao e as composicoes farmaceuticas que os contem
PT1056362E (pt) Processo para a preparacao de cargas fragmentadas para cigarros
FI956278A (fi) Substituoituja 4-fenyylitiatsolijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
PT939083E (pt) Complexos de ferro-succinilcaseina procedimento para sua preparacao e suas composicoes farmaceuticas

Legal Events

Date Code Title Description
FG Grant, registration